Author: toxlaw

Femoral blood is not guaranteed to preserve the concentration present at death after a long postmortem interval. In one extensively sampled autopsy, methamphetamine ranged from 268 to 911 ng/mL across nine blood locations after an estimated six to seven days. The authors proposed loss through venous walls as an explanation for part of the pattern, but the study did not directly measure that movement or establish the concentration during life.

The case and collection conditions

Wurita and colleagues investigated a 71-year-old man found dead in his apartment. His history included diabetes, chronic renal failure, hypertension, hepatitis and coronary disease. The body was kept in a refrigerated morgue at 2–4°C for six days before autopsy. Myocardial infarction was considered the direct cause of death, with methamphetamine discussed as a possible contributing influence rather than an independently established sole cause.

The investigators obtained 21 specimens: blood from nine cardiac or vascular locations, pericardial fluid, bile, stomach contents and nine solid tissues. No urine was available. Specimens were stored at −80°C until analysis. The estimated total postmortem interval and the period of refrigerated storage should not be confused with an experiment conducted continuously at ambient temperature.

The blood measurements

The right femoral venous result was 268 ±14.9 ng/mL, while left heart blood measured 911 ±46.2 ng/mL. Right heart blood measured 589 ±14.6 ng/mL. These are reported means and standard deviations from triplicate analytical determinations of specimens from one person, not variation across multiple deaths.

The pulmonary vein result, 567 ng/mL, was below left heart blood. Superior and inferior vena cava results were 566 and 415 ng/mL, and right iliac venous blood measured 409 ng/mL. Aortic arch and pulmonary arterial blood measured 733 and 805 ng/mL respectively. Simply labeling all of these specimens “central blood” would conceal material differences.

Amphetamine was also quantified as a methamphetamine metabolite. Its right femoral result was 7.28 ng/mL. Co-detection did not convert the case into a controlled exposure experiment with a known dose or administration time.

What the proposed diffusion mechanism means

The authors suggested that diffusion through relatively thin venous walls could reduce drug concentrations during a prolonged postmortem interval, while thicker arterial walls might retain drug differently. They also discussed contributions from organs and tissues.

These were interpretations of a distribution snapshot. There was no antemortem specimen, serial blood collection or direct measurement of passage through a vessel wall. A low femoral concentration relative to another site does not prove how much drug was lost. Nor does the highest measured blood result become a validated estimate of the concentration at death.

The authors suggested considering femoral skeletal muscle in this setting, but the single case did not validate a muscle-to-blood conversion. Tissue concentrations and blood concentrations must retain their respective ng/g and ng/mL units.

How the laboratory measurements were supported

Screening first identified amphetamines in pericardial fluid by immunoassay and methamphetamine in blood by GC–MS. Subsequent quantitation used liquid chromatography–tandem mass spectrometry with deuterated internal standards, modified QuEChERS extraction and specimen-specific standard addition.

Reported detection and quantitation limits were approximately 0.5 and 1.0 ng/mL or ng/g respectively. Calibration correlations exceeded 0.99. Repeatability assessed in femoral blood, liver and stomach contents had relative standard deviations no greater than 10.8%. Matrix response in those examples ranged from 58.8% to 95.2%, and recovery ranged from 66.1% to 109%.

The authors did not supply conventional accuracy and precision validation for every matrix, instead presenting repeated determinations in selected specimens. Good analytical repeatability does not resolve the separate uncertainty about biological change before collection.

The practical interpretive limit

The study supports recording the exact vessel or cardiac compartment and the collection timeline. It does not supply a universal correction, an impairment threshold or a fatal concentration. For related distinctions, see what specimen ratios can establish and analytical identification versus postmortem interpretation.

Primary source

Wurita A, Hasegawa K, Minakata K, et al. Postmortem redistribution of methamphetamine and amphetamine in blood specimens from various blood vessels and in the specimens from pericardial fluid, bile, stomach contents and various solid tissues collected from a human cadaver. Forensic Toxicology. 2016;34:191–198. https://doi.org/10.1007/s11419-015-0303-8.

A 2020 analysis estimated severe mental illness in 32.1% of a survey-defined group reporting methamphetamine and opioid use. That figure was an adjusted population estimate generated using a predictive model. It was not the percentage of people clinically diagnosed with methamphetamine-induced psychosis, and it did not establish which condition or exposure came first.

Who was included?

Shearer and colleagues pooled 2015–2018 National Survey on Drug Use and Health data for adults aged eighteen to sixty-four. The unweighted analytical sample included 156,870 respondents. Within it, 1,511 met the study’s opioid-use-only definition, 1,081 met its methamphetamine-use-only definition and 397 met both definitions.

Those subgroup counts are actual survey observations. They differ from weighted population totals and from the denominator used to interpret an adjusted percentage. The 32.1% estimate should not be converted into an observed case count simply by multiplying it by 397.

This was a cross-sectional observational analysis of historical U.S. civilian, noninstitutionalized survey data. It did not administer either substance or follow a newly exposed group to determine incident mental illness.

What did “opioid use” and “methamphetamine use” mean?

The definitions were intentionally asymmetric. Methamphetamine use meant any reported use in the preceding year. Opioid use meant any past-year heroin use or prescription opioid misuse on four or more occasions in the preceding month. It did not mean every instance of medically directed opioid treatment or every isolated episode of prescription misuse.

The group reporting both met these operational criteria. Its members were not necessarily exposed to both substances simultaneously. “Methamphetamine alone” meant without meeting the specified opioid-use definition; it did not mean no alcohol, cannabis or other drug exposure.

These distinctions affect the comparison population. An analysis using any past-year prescription opioid misuse, current weekly use or toxicology-confirmed simultaneous exposure would pose different questions.

How was severe mental illness determined?

The researchers used a predictive model validated by the Substance Abuse and Mental Health Services Administration. Inputs included the K6 Psychological Distress Scale, the World Health Organization Disability Assessment Scale, past-year suicidal ideation, past-year major depressive disorder and age.

This approach estimates a broad mental-health classification. It does not identify schizophrenia, a particular psychotic episode, methamphetamine-induced psychosis or intoxication at a specified time. The analysis did not provide the individual diagnostic history needed to attribute one person’s symptoms to one drug.

What were the estimates and their uncertainty?

Table 3 reported adjusted severe-mental-illness estimates of 20.7% for the opioid-only group, 22.8% for the methamphetamine-only group and 32.1% for the group reporting both. Their 95% confidence intervals were 17.3%–24.0%, 17.8%–27.8% and 25.0%–39.1%, respectively.

The comparison between the group reporting both and the opioid-only group met the table’s p≤0.01 criterion. The authors described the 32.1% estimate as approximately 55% higher than 20.7%. That is a relative comparison, corresponding to an absolute difference of about 11.4 percentage points. It is not a 55-percentage-point increase or a measured causal effect.

The table adjusted estimates for age, sex, income, education, rural versus urban residence, race/ethnicity and housing instability. Adjustment helps compare groups on measured characteristics. It cannot establish temporal order or remove unmeasured differences.

Did every health measure show a difference?

No. Estimated disability was high across all three groups: 37.7%, 40.0% and 42.1%, respectively. The disability row did not identify statistically significant between-group comparisons. Its broad definition included reported difficulty with seeing, hearing, concentrating, mobility, self-care or doing errands alone.

The authors also reported no statistically significant group differences in diabetes, kidney disease or cancer. These null findings should remain visible rather than being absorbed into a claim that every health outcome was worse in the combined-use group. Nonsignificance does not prove equivalence or absence of disease.

Why can’t the association establish which condition caused which?

Drug-use reports and health characteristics were assessed cross-sectionally. The authors explicitly could not determine the timing of drug-use initiation relative to health-condition diagnoses. Mental-health difficulties could precede, follow or share underlying causes with substance-use patterns.

Recall, disclosure and unrecognized exposure can affect self-report. The survey excluded incarcerated people and people who were homeless and unsheltered, populations relevant to estimating the broader burden. The findings also cannot be assumed to describe today’s drug supply or treatment environment.

For a client-ready interpretation, retain the study’s drug definitions, modeled classification, adjusted percentages and historical sampling frame. The research identifies a population with potentially substantial service needs. It supplies neither a diagnosis for an individual nor evidence that methamphetamine caused that individual’s mental illness, disability or impairment.

Scientific source

Shearer RD, Howell BA, Bart G, Winkelman TNA. Substance use patterns and health profiles among US adults who use opioids, methamphetamine, or both, 2015–2018. Drug and Alcohol Dependence. 2020;214:108162. doi:10.1016/j.drugalcdep.2020.108162. Historical cross-sectional human survey analysis; full author manuscript read from the supplied research collection.

A historical U.S. survey analysis reported that past-year methamphetamine use approximately doubled among respondents who also reported past-year LSD use. That finding describes a changing population percentage. It does not show that LSD caused methamphetamine use, that individuals progressed from one drug to the other, or that the substances were taken together on a particular occasion.

Which population and years were studied?

Palamar, Han and Keyes analyzed 226,632 respondents aged twelve and older in the 2015–2018 National Survey on Drug Use and Health. These were annual cross-sectional surveys of the noninstitutionalized population, not repeated follow-up interviews with one cohort.

The analysis used survey weights and accounted for the complex sampling design. The sample count is therefore different from the population represented by the weighted percentages. The findings concern 2015–2018 and are not estimates of present-day prevalence.

Earlier years were not pooled because the survey was redesigned in 2015, including changes to questions about methamphetamine and other drugs. A visually continuous trend across that redesign would require additional justification.

What exactly doubled?

Among respondents reporting LSD use in the preceding year, estimated past-year methamphetamine use increased from 5.1% in 2015 to 10.3% in 2018. The reported 95% confidence intervals were 3.4%–7.7% and 7.3%–14.3%, respectively. The linear trend had p=0.002.

The paper reported a 100.4% relative increase and a 5.2-percentage-point absolute increase. A relative increase near 100% means the starting percentage approximately doubled; it does not mean that nearly everyone in the subgroup reported methamphetamine use. Published percentages are rounded, so recalculating relative changes from the displayed endpoints need not reproduce the authors’ result exactly.

The denominator was people reporting past-year LSD use. The result is not the percentage of people reporting methamphetamine use who also reported LSD, and neither percentage is the prevalence of methamphetamine use in the entire population.

How did the whole-population trend differ?

The authors reported overall past-year methamphetamine prevalence rising from approximately 0.62% to 0.70%, with p=0.039 and a reported relative increase of 13.2%. The much larger change in the LSD-reporting subgroup therefore answers a narrower question than the modest overall change.

Other drug-defined subgroups also showed increases, including those reporting heroin, cocaine, ecstasy/MDMA or prescription opioid misuse. These categories overlap. A respondent can belong to several, so their estimated changes cannot be added as if they describe mutually exclusive populations.

Was the LSD finding just a reflection of heroin reporting?

The researchers repeated the analysis among respondents who did not report past-year heroin use. Within that restricted population, methamphetamine use among people reporting LSD increased from 4.3% to 8.1%, with a reported relative increase of 86.6% and p=0.019.

This sensitivity analysis makes the descriptive finding more specific: it persisted after excluding respondents reporting heroin. It does not remove every possible shared influence or establish a causal effect of LSD. Other drug use, social circumstances and differences in the composition of each annual subgroup can remain relevant.

The paper also found smaller quadratic trends for some prescription-drug categories in that restricted analysis. A quadratic trend is not interchangeable with a steady linear increase. Preserving the model description matters when a claim concerns how prevalence changed over time.

Can the survey show that the drugs were used together?

Both reports concerned the preceding year. The survey analysis did not establish the interval between methamphetamine and LSD use, the sequence of initiation, simultaneous ingestion, dose, purity or route on a particular occasion. It included no paired blood concentrations identifying a pharmacological interaction.

A change in an annual subgroup can also occur without the same individuals changing their behavior. Each year’s respondents and the population represented by that subgroup may differ. Describing this result as proof that LSD users individually moved on to methamphetamine would turn a repeated cross-sectional comparison into a longitudinal claim.

Which uncertainties belong in a client explanation?

The authors identify possible underrepresentation and underreporting of methamphetamine and heroin use, declining survey response and limited geographic detail. Unrecognized exposure would also escape a question asking respondents whether they used a drug. Self-report is not a chemical confirmation of every exposure.

The paper examined numerous demographic and drug-use trends; its methods describe trend models rather than a blanket correction for all comparisons. The reported p-values should be presented with that exploratory setting, the confidence intervals and the study’s sampling limits.

The supported conclusion is that this historical survey detected a substantial relative change within a particular reporting subgroup. It can motivate further research into contexts and prevention needs. It cannot determine the exposure history, diagnosis, impairment or causal pathway of an individual client.

Scientific source

Palamar JJ, Han BH, Keyes KM. Trends in characteristics of individuals who use methamphetamine in the United States, 2015–2018. Drug and Alcohol Dependence. 2020;213:108089. doi:10.1016/j.drugalcdep.2020.108089. Historical repeated cross-sectional human survey analysis; full author manuscript read from the supplied research collection.

A compound can appear to protect an animal’s dopamine system from methamphetamine while also reducing the animal’s rise in body temperature. Unless the experiment separates those effects, the result cannot establish that the compound’s proposed molecular target was solely responsible for protection. A 2006 review by Riddle, Fleckenstein and Hanson makes temperature control central to interpreting this research.

What kind of evidence does the paper provide?

This is a historical mechanistic review, not a new human trial or a meta-analysis estimating treatment benefit. It synthesizes experimental work on methamphetamine-related dopaminergic changes, drawing heavily on animal and laboratory preparations. Its account concerns mechanisms implicated by particular exposure regimens, especially repeated high-dose administration.

There is no single participant count, administered dose, route or observation interval for the review as a whole. Those details vary across its cited experiments. The discussion below attributes experimental findings to the review rather than claiming that each underlying primary dataset was independently reanalyzed.

Why is temperature part of the causal question?

The authors describe hyperthermia as an important contributor to persistent dopaminergic deficits in the experimental literature. Studies in which a treatment prevents the temperature increase can therefore show less injury for more than one reason: action on the hypothesized neural pathway, alteration of temperature, or both.

This is especially relevant when a drug changes dopamine or glutamate signaling and also changes thermoregulation. A comparison between methamphetamine alone and methamphetamine plus that drug does not automatically isolate the receptor or signaling pathway. The groups may differ in a second biologically consequential exposure: their temperature course.

For example, the review discusses the NMDA-receptor antagonist MK801. Protection against persistent dopaminergic deficits supported a possible role for glutamate signaling, but MK801 also prevented methamphetamine-associated hyperthermia. The review identifies that linked temperature effect as a complication in assigning the mechanism of protection.

Does that mean glutamate findings were entirely explained by cooling?

No. The same review describes evidence supporting glutamate involvement beyond temperature changes. It discusses posttreatment experiments with NMDA antagonists after amphetamine analog exposure and findings with metabotropic glutamate receptor 5 antagonists described as temperature independent. These are different experimental comparisons; they should retain their original drug and timing distinctions.

The authors also recognize remaining uncertainty. An antagonist might reduce glutamate release rather than identify every downstream step responsible for injury. Evidence that weakens one alternative explanation does not establish a complete, exclusive pathway.

How could an experiment distinguish the explanations?

The review emphasizes considering body-temperature responses and, when an intervention suppresses hyperthermia, examining what happens when elevated temperature is restored. The interpretive question is whether the apparent protection persists when the temperature difference is addressed.

A useful study appraisal therefore identifies the temperature measurement schedule, actual temperature trajectories, exposure regimen and injury endpoint. Merely stating that two groups were housed in the same room does not demonstrate that their bodies experienced the same temperature. Nor does an unreported temperature result establish that temperature was unchanged.

This is a design principle derived from the review’s reasoning, not a clinical instruction to manipulate temperature. The review does not supply a validated human temperature threshold that predicts a particular amount of brain injury.

Which biological endpoint was protected?

The paper distinguishes dopamine transporter function, transporter protein, vesicular storage, reactive species and persistent dopamine-system deficits. These measurements are related but not interchangeable. An acute functional change in a transporter can differ from a later persistent loss of a marker.

For example, the review describes rapid, reversible transporter changes after a single high-dose exposure and more persistent changes after repeated high-dose injections. It also discusses mitochondrial disruption, oxidative processes, dopamine receptors and vesicular monoamine transporter trafficking. The resulting model involves interacting processes rather than one laboratory measurement explaining every consequence of methamphetamine exposure.

What does this mean for a human case?

Animal neuroprotection findings can help generate hypotheses and improve experimental design. They do not establish that a proposed protective compound prevents injury in people, reverses an established condition, or is appropriate treatment. Protection before an experimental exposure and recovery after an exposure are separate questions.

Likewise, the review cannot translate a positive human methamphetamine test into proof of hyperthermia, irreversible neuronal loss or impairment at a particular event. Those conclusions require their own evidence. Its practical contribution is a sharper question for evaluating a mechanistic claim: did the experiment isolate the proposed target, or did a consequential temperature difference travel with the intervention?

Scientific source

Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. The AAPS Journal. 2006;8(2):E413–E418. doi:10.1007/BF02854914. Historical mechanistic review; original commentary based on the full paper recovered from the supplied research collection.

A statistically significant ethanol storage-loss equation is not necessarily accurate enough to correct an individual result. In a 2007 study of preserved blood, the investigator explicitly warned against using the regression to predict a specimen’s loss because individual variation remained large. Applying that equation to postmortem blood would add a further, untested transfer between specimen populations.

Three datasets served different purposes

Jones studied venous whole blood from living drivers in Sweden. Blood was collected from an antecubital or cubital vein into 10-mL evacuated glass tubes containing 100 mg sodium fluoride and 25 mg potassium oxalate. Tubes were mixed after collection and refrigerated at 4°C.

The study used 4,739 cases to characterize analytical imprecision across ethanol concentrations. A separate set of 159 specimens supported the storage-change analysis for intervals up to 12 months. Another experiment used paired tubes from 49 drivers to compare repeated opening with unopened storage. These denominators should not be combined into one storage cohort.

None of these groups consisted of decomposed autopsy specimens. The paper discussed microbial difficulties with postmortem blood, but did not experimentally validate its storage model in that matrix.

A precise assay still showed variable specimen change

Ethanol was determined in duplicate by headspace gas chromatography, with independent technicians and equipment. At the mean blood ethanol concentration of 1.64 mg/g, the estimated standard deviation of a single determination was 0.019 mg/g, corresponding to approximately 1.1% CV.

Among the 159 storage specimens, the mean decrease was 0.105 mg/g with SD 0.0686 mg/g. The change was statistically significant, p < 0.001. Loss correlated with storage duration, r = 0.44, and with starting concentration, r = 0.23. Both associations were statistically significant, but neither implied that a particular tube followed the average.

One specimen showed a small increase of 0.006 mg/g after two weeks, which was analytically insignificant. The study found no significant increase under its tested conditions. This is different from demonstrating that all preserved postmortem specimens are protected against ethanol formation.

The regression and its explicit limitation

The reported equation was:

Predicted decrease in mg/g = 0.0306 + 0.000306 × storage days + 0.0151 × the study’s blood ethanol term (BEC), in mg/g.

The multiple correlation coefficient was 0.467, with p < 0.001. Both predictor coefficients were statistically significant. However, the residual standard deviation was 0.061 mg/g. The author therefore stated that the equation should not be used to predict individual storage loss.

Statistical significance indicates that the observed association was unlikely to be explained by the tested null model. It does not make unexplained between-tube variation disappear. Adding a calculated “lost amount” back to a later result would present an individual correction the source expressly declined to support.

Opening history supplied another source of variation

In the 49-driver paired-tube experiment, tubes opened 17 times over 6.5 months lost an average of 0.217 mg/g, compared with 0.101 mg/g in tubes kept unopened. Their respective SDs were 0.054 and 0.076 mg/g; the difference was significant, p < 0.001.

Those group means do not provide fixed corrections for opened and unopened tubes. They show why storage duration alone does not describe the complete specimen history. Container integrity, handling and preservative conditions remain relevant. Our article on opened and underfilled tubes discusses related handling questions.

The additional limit for a death investigation

The results were reported in mg/g whole blood. They are not automatically interchangeable with serum concentrations or with a volume-based result expressed in g/L. More fundamentally, samples collected from living drivers under the stated conditions do not reproduce bacterial contamination, decomposition or precollection change in a cadaver.

The study can support asking for documented handling conditions and method imprecision. It cannot reconstruct ethanol at death, prove antemortem drinking or quantify postmortem formation. A separate serial-testing postmortem case illustrates why formation and storage loss are separate possibilities that require their own evidence.

Primary source

Jones AW. Are changes in blood-ethanol concentration during storage analytically significant? Importance of method imprecision. Clinical Chemistry and Laboratory Medicine. 2007;45:1299–1304. https://doi.org/10.1515/CCLM.2007.289.

A drug-positive larva does not, by itself, establish that all of its detected compounds came from the remains on which it was collected. A five-rabbit field experiment reported unexpected carbamazepine findings in larvae collected from a clobazam-treated carcass. The authors attributed that finding to movement between carcasses, illustrating why collection location and prior feeding history are separate questions.

The field experiment

Boulkenafet and colleagues studied five male rabbits weighing approximately 1.3–2.5 kg in an urban setting in Skikda, Algeria, at recorded environmental temperatures ranging from 8°C to 25°C. One rabbit was a water-treated control. Two received carbamazepine and two clobazam, with one rabbit at each of the study’s designated toxic and lethal dose levels.

The reported carbamazepine doses were 1,710.5 and 3,271.57 mg/kg; clobazam doses were 185.94 and 414.08 mg/kg. These were experimental animal doses, not human toxicity thresholds. The lethal-dose rabbits reportedly died immediately after dosing; the remaining rabbits were killed by slaughter. Carcasses were placed 20 m apart in cages that admitted insects while excluding larger predators.

Each treatment condition therefore had one carcass. Hundreds of insects did not supply independent replication of the rabbit-level dosing conditions.

What was collected and measured

Collection continued for 46 days, with sampling three times daily initially, then twice daily and finally once daily. Neck epidermal and muscle tissue was sampled immediately after death and additional tissue was taken every 48 hours. Selected larvae were retained for development observations; others were frozen at −20°C for toxicology. Tissue storage was described separately in the paper.

The authors reported 800 larvae used for toxicological analysis and a total insect collection of 1,150. The species counts in the paper’s table sum to 1,177, so the total should not be treated as an internally reconciled denominator. The species were Lucilia silvarum, Lucilia sericata and Chrysomya albiceps.

Drug investigation used methanol extraction and ultra-high-performance liquid chromatography with quadrupole time-of-flight mass spectrometry. Although the method is described as quantitative, the reported findings emphasized chromatograms and retention times rather than a validated concentration dataset. The paper did not provide a full matrix-specific validation package of detection limits, quantitation limits, recovery and measurement uncertainty for these larval results.

The finding that raised the migration question

Larvae collected from the rabbit given the higher clobazam dose showed carbamazepine and carbamazepine-epoxide signals, although the authors reported those compounds absent from that carcass’s tissue. They inferred that larvae had migrated from a carbamazepine-treated carcass.

That interpretation was plausible within the experiment, but the insects were not individually tracked. The observation was not a validated test for reconstructing a larva’s movements or identifying a unique source carcass. It does show why a collection label alone cannot prove a complete exposure history.

The authors also reported failure to obtain adequate larvae for toxicology from the high-dose carbamazepine carcass because early larval mortality was increased. Consequently, lack of a usable insect specimen is not equivalent to a negative toxicology result.

Detection, metabolism and source attribution need different evidence

The article contains inconsistent assignments for some metabolite signals. For example, an approximately 8.09-minute signal is described differently in the tissue and larval discussions. Those assignments should not be promoted into a validated metabolic pathway or used to calculate exposure timing.

Finding a parent drug and a metabolite in insects also does not establish where metabolism occurred. Possible transfer from feeding tissue must be distinguished from metabolism within the insect. The experiment did not establish a numerical relationship between a larval finding and the rabbit’s blood concentration, much less a human antemortem concentration.

What the study supports in a case review

Preserving the exact insect collection location, species, developmental stage and handling history is central to evaluating what a result can mean. Companion tissue findings can expose discrepancies that a larval result alone would conceal. A positive insect result may support further investigation; it cannot independently establish impairment, dose, cause of death or exclusive feeding on one set of remains.

These provenance limits complement the broader problem of interpreting alternative specimens and the analytical need for validation in the actual matrix.

Primary source

Boulkenafet F, Dob Y, Karroui R, et al. Detection of benzodiazepines in decomposing rabbit tissues and certain necrophagic dipteran species of forensic importance. Saudi Journal of Biological Sciences. 2020;27:1691–1698. https://doi.org/10.1016/j.sjbs.2020.04.044.

A drug can affect insect weight without shortening the insect’s overall development cycle. A controlled 2025 experiment with Calliphora vicina found higher weights after exposure to clonazepam or flunitrazepam, particularly at later developmental stages, while reporting similar total development times. Weight and developmental age therefore should not be treated as interchangeable endpoints.

Why this matters to decomposed-remains investigations

Insect development can contribute to estimation of a minimum postmortem interval. If drugs in a feeding substrate change larval size or weight, comparison with an unexposed reference may be misleading. That possibility does not itself supply a correction in hours or days for a human death.

Iancu, Wellens and Sahlean tested two drugs in one fly species under controlled conditions. This was not a human autopsy study and did not determine drug concentrations in human blood, decomposing human tissue or individual larvae.

Experimental conditions and replication

Three adult colonies, each containing 300 flies, were maintained at 24°C, 50% humidity and a 12:12-hour light–dark cycle. Eggs were transferred into nine rearing containers: three control containers, three clonazepam containers and three flunitrazepam containers. Each held 200 g of minced beef liver and three egg clusters of approximately 250 eggs each.

The drug preparations were 4 mg clonazepam in 50 mL water and 2 mg flunitrazepam in 50 mL water, giving initial solution concentrations of 0.08 and 0.04 mg/mL respectively. These were feeding-substrate preparations, not measured concentrations within insects. The experiment tested one preparation level for each drug, not a full dose–response series.

The researchers reported 2,700 weighing measurements across developmental stages. Specimens were selected without destructive sampling and separated during each weighing session to avoid weighing the same individual twice in that session. The number of measurements does not represent 2,700 independent rearing experiments; the nine containers and their treatment assignments remain important to understanding replication.

Significant weight effects and important null findings

An aligned rank transform analysis found a significant interaction between treatment and developmental stage: F(8, 28.628) = 8.2309, p < 0.0001. Overall median weights were higher than control for clonazepam and flunitrazepam exposure. The overall comparison between the two drugs was not significant, p = 0.4191.

The effects depended on stage. Early first- and second-instar comparisons did not show the same differences seen later. Clonazepam’s significant stage-specific effects were concentrated around the transition from third-instar larvae to pupae. Flunitrazepam showed broader later-stage differences. The paper also reported a between-drug difference at the pupae-to-teneral transition, so the overall null comparison should not be described as proof of identical effects at every stage.

In contrast, total development from oviposition to newly emerged adult was approximately 546 hours in all three treatment groups, with no notable difference in cycle length. There was also no evidence of an association between treatment and the sex distribution of emerged flies, p = 0.939.

The endpoint determines the inference

A heavier specimen might be read as more advanced if weight alone is used as a developmental indicator. Here, that interpretation would miss the finding that total cycle duration remained similar. Conversely, the null cycle-duration result does not erase the observed weight effects.

The study does not quantify a universal error in minimum postmortem interval estimates. It used one species, constant conditions, a defined food substrate and specific drug preparations. Human remains involve variable temperatures, access and colonization times, tissue conditions and possible mixtures of substances. Those were not reproduced by this experiment.

This was not a drug-detection validation study

The researchers measured development and weight. They did not validate a toxicological assay for insects or establish a conversion from larval concentration to human dose. A morphological response cannot identify which drug was present in an unknown specimen, prove impairment or establish why a person died.

The defensible use is to recognize that drug exposure may affect one developmental measure without affecting another. Analytical confirmation remains a separate task, as explained in our discussion of specimen-based assay validation. The distinction between detection and interpretation also applies to alternative postmortem matrices.

Primary source

Iancu L, Wellens M, Sahlean T. Effects of clonazepam and flunitrazepam on the development cycle of Calliphora vicina Robineau-Desvoidy 1830 and their forensic implications. Scientific Reports. 2025;15:22773. https://doi.org/10.1038/s41598-025-05766-8.

A metabolite reported as a strong chromatographic peak has not necessarily been quantitatively measured. In a detailed MDMB-CHMICA autopsy investigation, relative metabolite signals helped identify useful analytical targets, but they did not establish metabolite concentrations, amounts in the body or a precise time of exposure.

What was studied in the laboratory and the autopsy

Gaunitz and colleagues combined one human postmortem case with duplicate pooled human liver microsome incubations and a negative incubation control. The microsomal experiment used a final MDMB-CHMICA concentration of 4 µg/mL. The autopsy was performed approximately 12 hours after the death of a 27-year-old man following a high fall.

Blood, urine, tissues and gastric content were available. Parent-drug MDMB-CHMICA was quantified separately, including 1.7 ng/mL in femoral blood. THC, amphetamine and MDMA were also present in femoral blood. The metabolite investigation was therefore conducted alongside, rather than in place of, a broader multidrug examination.

Product-ion scans supplied structural evidence

The investigators screened proposed metabolite pathways by liquid chromatography–electrospray tandem mass spectrometry using product-ion scans at two collision energies. Monohydroxylated metabolites were investigated at precursor m/z 401; ester hydrolysis at m/z 371; hydrolysis plus hydroxylation at m/z 387; and hydrolysis plus two hydroxylations at m/z 403. Fragment patterns helped assign which part of the molecule had changed.

The microsomal work detected seven monohydroxylated metabolites: six assigned to hydroxylation of the cyclohexylmethyl portion and one to hydroxylation of the indole portion. Additional signals were not accepted as further identified metabolites when suitable fragment evidence was lacking. Some apparent signals also occurred in negative controls and were attributed to matrix components.

This distinction matters: a peak at an expected precursor mass is a candidate signal, not automatically a confirmed metabolite. Reference evidence, fragmentation and controls determine how far identification can go.

The most abundant signal depended on the specimen

Monohydroxylated metabolites predominated in the microsomal extracts and were detected in postmortem blood, liver, psoas muscle and urine. One metabolite peak was strongest in liver and urine, while a different peak was strongest in the blood specimens and psoas. A metabolite prominent in the latter matrices was not detected in liver or urine.

The ester-hydrolysis product was detected in liver but not urine in this case. Hydrolyzed products with further hydroxylation were also restricted to liver among the postmortem specimens examined. No metabolites were found in brain, kidney, lung or gastric content under the study’s screening conditions, even though parent drug was detected in those specimens.

These are detection findings from one case. Absence under a particular extraction and scan method does not establish biological absence of all metabolites. Differences in extraction, instrument sensitivity, collection timing and matrix remain possible influences.

Why “100% intensity” did not mean 100% of the drug

The study expressed metabolite signals relative to the most abundant metabolite signal. A value of 100% identified the reference peak for that comparison. It did not mean that the metabolite represented all of the drug-derived material, or that its concentration was known in ng/mL or ng/g.

Different compounds can generate different signal responses. Without validated metabolite-specific calibration and suitable standards, peak-height or peak-intensity comparisons cannot be treated as molar ratios. The parent-drug quantitation procedures do not automatically validate quantitative measurement of every metabolite screened.

Target selection is different from dating exposure

The authors considered monohydroxylated metabolites useful targets for detecting MDMB-CHMICA intake. They also interpreted parent drug in urine and a limited urinary metabolite pattern as supporting use near death. The study did not test a controlled series with known exposure times, so it cannot turn that pattern into an individual exposure clock.

Microsomal incubation is also an in vitro metabolism experiment, not a model of decomposition in a cadaver. Similarity between a microsomal product and an autopsy signal does not establish whether a particular concentration changed after death. Detection of parent drug and metabolites remains separate from proof of impairment or cause of death.

For complementary analytical distinctions, see accurate mass and compound identification and specimen choice for postmortem screening.

Primary source

Gaunitz F, Lehmann S, Thomas A, Thevis M, Rothschild MA, Mercer-Chalmers-Bender K. Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. International Journal of Legal Medicine. 2018;132:1645–1657. https://doi.org/10.1007/s00414-018-1911-8.

Brain tissue can add useful evidence when postmortem MDMB-CHMICA exposure is suspected, but its concentration cannot simply be substituted for a blood result. A 2018 case report found the synthetic cannabinoid in every specimen examined, with the highest measured tissue concentration in brain. This was one extensively investigated death, not validation of a universal specimen hierarchy.

One traumatic death with several co-exposures

Gaunitz and colleagues investigated a 27-year-old man who died after falling from the 24th floor of a building. Autopsy approximately 12 hours after death documented severe trauma. Samples included cardiac and femoral blood, urine, psoas major muscle, brain, liver, right lung, kidney and gastric content. The right lung, liver, kidney and stomach were described as uninjured; the head and upper body had substantial injuries.

Femoral blood contained MDMB-CHMICA at 1.7 ng/mL, THC at 9.3 ng/mL, amphetamine at 1,050 ng/mL and MDMA at 275 ng/mL. Additional findings included low-level or trace drug signals in other specimens. These co-exposures prevent treating the case as an isolated MDMB-CHMICA experiment. The authors could not determine whether the fall was accidental or associated with a drug-induced mental state.

The specimen-specific findings

MDMB-CHMICA measured 2.1 ng/mL in cardiac blood and 1.7 ng/mL in femoral blood. Tissue results included 5.5 ng/g in brain, 3.8 ng/g in kidney, 2.6 ng/g in liver and lung, and 1.2 ng/g in psoas major muscle. Urine contained 0.01 ng/mL. Gastric content contained 2.4 ng/g, corresponding to approximately 1.1 µg in the collected gastric contents.

The units must remain attached to the specimen. A tissue result in ng/g is not the same measurement as blood in ng/mL. These observations did not establish a conversion between brain and blood, and a higher numerical tissue result does not independently establish a greater pharmacological effect.

Gastric detection also did not prove oral ingestion. The authors discussed diffusion and a likely nonoral route, with inhalation considered plausible. No witnessed route or known administered dose was established by the distribution measurements.

How quantitation differed between matrices

Analysis used liquid chromatography–electrospray tandem mass spectrometry. Most specimens were quantified by five-point standard addition, in which known amounts of analyte were added to the specimen. Insufficient material prevented that approach for urine and lung; those specimens used three-point matrix calibration instead.

Calibration R² exceeded 0.99 except for brain, where it was 0.98. Selected detection limits were 0.005 ng/mL in urine, 0.05 ng/mL in femoral blood, 0.025 ng/g in kidney and 0.017 ng/g in brain, defined by a signal-to-noise ratio of at least three. These detection limits are not a complete set of quantitation limits or uncertainty estimates for every specimen.

High-resolution analysis of reference material and the urine and kidney specimens supported identification of MDMB-CHMICA and distinguished it from BB-22, which can have similar nominal-mass fragmentation. The two compounds have different exact masses. This identification step was separate from comparing how much drug occurred in different tissues.

What the blood ratio did not establish

The cardiac/femoral ratio was approximately 1.2. The authors interpreted it as not indicative of appreciable redistribution in this case. However, no antemortem concentration or serial postmortem collection was available. Similar concentrations at two postmortem sites cannot demonstrate that neither changed after death.

The approximately 12-hour collection interval likewise did not establish a general time at which redistribution becomes complete. The case supplies a distribution snapshot, with trauma and multiple drugs, rather than a time-course experiment. Our discussion of central-to-peripheral ratios near one explains that broader distinction.

Using the result without overstating it

The report supports considering brain among available specimens and retaining companion blood and tissue results. It does not supply an individual fatal threshold, a reconstruction of the dose, or proof that MDMB-CHMICA caused the fall. Collection site, matrix, analytical procedure and case circumstances remain necessary to interpretation. For related analytical issues, see authentic specimens and assay interference.

Primary source

Gaunitz F, Lehmann S, Thomas A, Thevis M, Rothschild MA, Mercer-Chalmers-Bender K. Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. International Journal of Legal Medicine. 2018;132:1645–1657. https://doi.org/10.1007/s00414-018-1911-8.

People can show different psychiatric symptom patterns during periods of more frequent methamphetamine use. That observation does not create a test that can reliably assign an individual’s symptoms to methamphetamine rather than another condition. A 2016 longitudinal study by McKetin and colleagues examined those patterns while explicitly acknowledging that temporal association did not establish direct causation.

Who was followed, and for how long?

The analysis included 164 community-recruited adults from Brisbane, Melbourne and Sydney who did not meet DSM-IV criteria for a lifetime primary psychotic disorder. Participants completed baseline assessment and up to 11 monthly follow-ups over one year. Recruitment included needle-and-syringe programs, advertisements and word of mouth; 88% had previously injected methamphetamine.

This was an observational cohort rather than controlled administration. The sample was predominantly White and Australian-born, with a mean age of 32.3 years. Those selection features matter when considering whether the patterns apply to people with different psychiatric histories, routes of use or backgrounds.

Did “more use” mean a larger measured dose?

No. The predictor was self-reported days of methamphetamine use in the preceding month, assessed with a timeline interview. Psychiatric symptoms for the same period were rated on the 24-item Brief Psychiatric Rating Scale, using scores from one to seven.

Days of use are a frequency measure. They do not specify milligrams, purity, enantiomer, route on each occasion or blood concentration. Referring to the findings as dose-related without explaining that proxy would imply more exposure precision than the study supplied.

What was the analytical denominator?

The investigators excluded 217 monthly observations during which participants reported antipsychotic or antidepressant medication, leaving 1,370 person-months for analysis. Those 1,370 observations came from the 164 participants; they were not 1,370 independently recruited people.

The models accounted for repeated observations and adjusted for selected concurrent substance use and psychosis risk factors. Nevertheless, excluding medicated months narrows the question. The results do not describe symptom behavior during all treatment states, and adjustment cannot eliminate every influence that changes alongside heavier use.

Which symptom dimensions emerged?

The researchers estimated how individual symptom ratings changed with use frequency, then explored correlations among those estimated changes. Three factors described predominantly affective symptoms, positive psychotic symptoms and psychomotor symptoms.

The affective dimension included features such as depression, suicidality and hostility. The positive psychotic dimension included suspiciousness, hallucinations and unusual thought content. The psychomotor dimension included motor hyperactivity, excitement and distractibility. Some symptoms loaded on more than one factor, so these were not completely separate symptom boxes.

Affective and positive psychotic factor scores were correlated, with a reported Spearman correlation of 0.61. Neither showed a comparable association with the psychomotor factor. This supports describing different patterns of symptom change within the sample; it does not demonstrate three distinct diseases or three exclusive biological mechanisms.

What did the reported 28% mean?

A subsequent latent-profile model assigned approximately half the sample to relatively low exacerbation across all three dimensions, 28% to greater affective and positive psychotic exacerbation, and 22% to greater psychomotor exacerbation. These were model-derived profiles of symptom changes, not population prevalence estimates of methamphetamine-induced psychosis.

The group with greater affective and psychotic exacerbation had a reported past-year substance-induced-psychosis prevalence of 38%, compared with 22% in each of the other profiles. However, the associated comparison had p=0.056 and did not meet the study’s p<0.05 threshold. It should not be presented as a statistically confirmed diagnostic separation.

Does the negative-symptom null result rule out schizophrenia?

No. The study did not detect a significant increase in negative symptoms with more days of methamphetamine use. That finding is different from showing that nobody experienced negative symptoms, that methamphetamine could never contribute to them, or that their absence identifies a substance-induced condition.

The authors specifically could not exclude negative symptoms emerging later as part of a residual profile. The study also excluded people with a lifetime primary psychotic disorder at entry. It therefore did not validate a clinical rule for distinguishing that disorder from methamphetamine-related symptoms in an unselected diagnostic population.

What remains uncertain about causation and individual application?

Symptoms and use were summarized over the same month. Unmeasured stressors, sleep changes, other substances and circumstances accompanying frequent use could contribute to the association. The authors called their causal working assumption pragmatic and explicitly stated that it was not intended to imply a direct causal relationship.

For a client explanation, distinguish reported exposure frequency, repeated symptom ratings, statistical profiles and a formal diagnosis. The paper did not establish sensitivity, specificity or an independently validated cutoff for an individual diagnostic test. Its strongest contribution is a more detailed description of heterogeneous symptom changes, with the null findings and uncertainty preserved.

Scientific source

McKetin R, Dawe S, Burns RA, Hides L, Kavanagh DJ, Teesson M, Young RM, Voce A, Saunders JB. The profile of psychiatric symptoms exacerbated by methamphetamine use. Drug and Alcohol Dependence. 2016;161:104–109. doi:10.1016/j.drugalcdep.2016.01.018. Historical longitudinal observational human study; original commentary based on the full accepted manuscript for the paper identified in the supplied collection.